HAYWARD, Calif.--Lynx Therapeutics and Hybrigenics of Paris are working together to discover expressed genes, protein interactions, and pathways in human obesity. Both companies intend to use the findings to create new diagnostics and treatments for this disease area.
Lynx will use its DNA cloning and analysis technologies to discover novel expressed genes in the formation and differentiation of human fat cells. Hybrigenics plans to expand these discoveries to identify the protein interactions and pathways involved in this process.